On February 13thth, Eevia Health Plc (publ) (“Eevia”) announced that the Company has initiated a EUR 2.6m sales transaction with Baccas Salus Oy, for equipment, products, and berry extract manufacturing IP. The transaction price exceeds the book value of the assets with EUR 1.5m, and the deal awaits approvals and payment from Baccas Salus Oy.

Länk till analysen